Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
Letters to the Editor

Familial hypercholesterolemia: Clarifications

Taher Modarressi, MD
Cleveland Clinic Journal of Medicine June 2020, 87 (6) 320; DOI: https://doi.org/10.3949/ccjm.87c.06001
Taher Modarressi
Diabetes & Endocrine Associates of Hunterdon Flemington, NJ 08822
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editor: The article by Shah and colleagues1 is an excellent review of familial hypercholesterolemia (FH) and highlights an underdiagnosed condition on which clinicians can make a significant impact. I would like to clarify two points:

First, as the authors describe, tendon xanthoma is mostly pathognomonic for FH. Xanthelasma, however, is nonspecific for this condition and does not appear in any of the diagnostic criteria.

Second, the American Diabetes Association (ADA) was one of the societies involved in the 2018 American Heart Association/American College of Cardiology multisociety guidelines,2 and the 2020 ADA Standards of Care still reflect a low-density lipoprotein cholesterol (LDL-C) threshold for intensification of 70 mg/dL in patients at very high risk.3 I believe the authors meant to refer to the 2017 American Association of Clinical Endocrinologists/American College of Endocrinology guidelines that introduced a new category of “extreme risk” with an LDL-C treatment goal of less than 55 mg/ dL, which includes patients with heterozygous FH and established atherosclerotic cardiovascular disease.4 This treatment goal was mirrored by the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines.5

  • Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Shah NP,
    2. Ahmed HM,
    3. Tang WH
    . Familial hypercholesterolemia: detect, treat, and ask about family. Cleve Clin J Med 2020; 87(2):109–120. doi:10.3949/ccjm.87a.19021
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Grundy SM,
    2. Stone NJ,
    3. Bailey AL, et al
    . 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139(25):e1082–e1143. doi:10.1161/CIR.0000000000000625
    OpenUrlCrossRefPubMed
  3. ↵
    1. American Diabetes Association
    . 10. Cardiovascular disease and risk management: standards of medical care in diabetes — 2020. Diabetes Care 2020; 43(suppl1):S111–S134. doi:10.2337/dc20-S010
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Jellinger PS,
    2. Handelsman Y,
    3. Rosenblit PD, et al
    . American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 2017; 23(suppl 2):1–87. doi:10.4158/EP171764.APPGL
    OpenUrlCrossRefPubMed
  5. ↵
    1. Mach F,
    2. Baigent C,
    3. Catapano AL, et al
    . 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020; 41(1):111–188. doi:10.1093/eurheartj/ehz455
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 87 (6)
Cleveland Clinic Journal of Medicine
Vol. 87, Issue 6
1 Jun 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Familial hypercholesterolemia: Clarifications
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Familial hypercholesterolemia: Clarifications
Taher Modarressi
Cleveland Clinic Journal of Medicine Jun 2020, 87 (6) 320; DOI: 10.3949/ccjm.87c.06001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Familial hypercholesterolemia: Clarifications
Taher Modarressi
Cleveland Clinic Journal of Medicine Jun 2020, 87 (6) 320; DOI: 10.3949/ccjm.87c.06001
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Antiobesity drug therapy
  • Physician resistance to obesity pharmacotherapy
  • In Reply: Physician resistance to obesity pharmacotherapy
Show more Letters to the Editor

Similar Articles

Subjects

  • Endocrinology
  • Genetics
  • Preventive Care
  • Diabetes
  • Dermatology
  • Cardiology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire